Put companies on watchlist
Cosmo Pharmaceuticals N.V.
ISIN: NL0011832936
WKN: A2AJ68
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

Cosmo Pharmaceuticals N.V. · ISIN: NL0011832936 · EQS - Company News (74 News)
Country: Ireland · Primary market: Netherlands · EQS NID: 1583775
16 March 2023 07:00AM

Invitation to Cosmo’s full-year 2022 financial results and 2023 outlook webcast presentation on 23 March 2023


Cosmo Pharmaceuticals N.V. / Key word(s): Annual Results
Invitation to Cosmo’s full-year 2022 financial results and 2023 outlook webcast presentation on 23 March 2023

16.03.2023 / 06:00 GMT/BST


Dublin, Ireland – 16 March 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) announced today that it will publish its full-year 2022 results on Thursday, 23 March 2023 at 07:00 am CET.

 

Cosmo invites investors, financial analysts and business/life science journalists to a live video webcast which will follow at 2:00 pm CET with Mauro Ajani, Founder and Chairman, Alessandro Della Chà, CEO, and Niall Donnelly, CFO, to discuss the 2022 financial and operating results as well as the next milestones of the company.

 

Live conference call and video webcast presentation:

Date:  Thursday, 23 March 2023
Time:  2:00 pm CET

Webcast link: Chrome (recommended) or Firefox https://media.choruscall.eu/mediaframe/webcast.html?webcastid=L3HNXtf4


Please note that there is a function to type in your questions via webcast.

Via phone:

Participants wishing to ask verbal questions via phone, may call the following numbers below. To ensure prompt access, please call approximately ten minutes prior to the scheduled start of the call.

Switzerland / Europe

+41 (0) 58 310 50 00

United Kingdom

+44 (0) 207 107 06 13

United States

+1 (1) 631 570 56 13

 

The presentation and media release as well as the Annual Report 2022 will be available for download as of 07:00 am CET on 23 March 2023 at www.cosmopharma.com


Replay

The webcast, along with the presentation, will be available online shortly after the event and accessible for three months.

 

 

Contact:

Hazel Winchester

Head of Investor Relations

Cosmo Pharmaceuticals N.V.

Tel: +353 1 817 03 70

hwinchester@cosmopharma.com



End of Media Release


Language: English
Company: Cosmo Pharmaceuticals N.V.
Riverside 2, Sir John Rogerson’s
Dublin 2 Dublin
Ireland
Phone: + 353 1 817 0370
E-mail: info@cosmopharma.com
Internet: https://www.cosmopharma.com/
ISIN: NL0011832936
Listed: SIX Swiss Exchange
EQS News ID: 1583775

 
End of News EQS News Service

1583775  16.03.2023 GMT/BST

fncls.ssp?fn=show_t_gif&application_id=1583775&application_name=news&site_id=boersengefluester_html
Visual performance / price development - Cosmo Pharmaceuticals N.V.
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2025
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.